WinstonWınston
Back
Laboratorios Richmond S.A.C.I.F. logo

Laboratorios Richmond S.A.C.I.F.

RICH.BA
47
Drug Manufacturers - Specialty & Generic · Healthcare
Exchange
Buenos Aires Stock Exchange
Winston Score
47
Winston is serious
Mixed quality — meaningful strengths and weaknesses.
Data as of Aug 23, 2026 · filings through Jun 30, 2026
How the score breaks down
Quality
Mixed
Growth
Mixed
Cash Flow
Good
Stability
Mixed
Valuation
Good
Dividends
Mixed

Winston Score History

The full picture

Laboratorios Richmond is an Argentine pharmaceutical company that makes and sells medicines for people and animals. Its products include branded generic drugs — copies of well-known medicines sold under its own labels — covering areas like cardiology, diabetes, and infectious diseases. The company sells mainly to pharmacies, hospitals, and healthcare distributors across Argentina and other Latin American markets.

Richmond earns money by manufacturing and selling these drugs directly, keeping a strong gross margin above 60% thanks to its own production facilities and established brand recognition in Argentina. The company operates primarily in Argentina, which makes it heavily exposed to that country's economic instability, including high inflation and currency controls that can erode real profits. Its main growth opportunity lies in expanding its product portfolio and increasing exports to neighboring countries, but Argentina's volatile macroeconomic environment remains the single biggest risk to its financial performance.

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+30.3% YoY

YoY Growth Rate

Strong revenue growth

EPS Growth

-207.7% YoY

YoY Growth Rate

Earnings declining

Insider Activity

82.5%ownership

Insiders own a meaningful stake in the company

Cash Position

Cash flow positive

5.6B ARS cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

Company generates more cash than it spends — no dilution risk from fundraising

Strong grower

Laboratorios Richmond S.A.C.I.F. is growing revenue at 30% year-over-year. The Winston Score penalises unprofitable companies, but revenue at this pace tells a different story — this is a company still in "build mode."

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale
Gross Margin
50.9%
Healthy — 50.9% gross margin
Profit after running costs
Operating Margin
7.5%
Modest — 7.5% operating margin
Return on the money invested
ROCE
6.8%
Weak — 6.8% return on capital

ROIC between 5% and 15%. They earn 5 to 15 cents back per year on every dollar invested.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth
Sales YoY
+24.0%
Fast-growing sales (+24.0% YoY)
Profit growth
EPS YoY
-10.5%
Earnings shrinking (-10.5% YoY)

Earnings per share down more than 10%. Either a bad year, or a real decline.

How steady the profit is
EPS Consistency
4/8 quarters
Earnings inconsistent quarter-to-quarter

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash
Cash Conversion
111%
Turns 111% of profit into real cash
Spare cash per sale
FCF Margin
-34.8%
Burning cash (-34.8%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns
Debt / Equity
1.89
Elevated debt (1.89)
Covers its interest
Interest Cover
1.62x
Dangerous — barely covers interest (1.6x)

Interest coverage between 1 and 3. Profits cover interest, but with little room to spare.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit
P/E Ratio (TTM)
9.7x
no trend
Attractive valuation — P/E 9.7

P/E under 10. The price tag is small relative to last year's profit.

Cheaper or dearer next year
P/E vs Forward
N/A
not available
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Dividend
Dividend Yield
2.08%
no trend
Moderate income — 2.08% yield

Standard yield zone for stable dividend payers. A meaningful piece of total return.

Dividend record
Dividend Growth
N/A
no trend
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial